Clinical trial · Interventional
The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma
The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial
NCT01820884CI-TRIAL-00075599EC-02active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized trial is studying the efficacy and safety of the hysterectomy alone compared with hysterectomy and bilateral salpingo-oophorectomy (BSO) for patients with Stage IA endometrial carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Neoplasms | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BPLND | Procedure | — | UNRESOLVED |
| TH | Procedure | — | UNRESOLVED |
| TH/BSO | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Total Hysterectomy (TH)
- description
- Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
- interventionNames
- Procedure: TH
- Procedure: BPLND
- type
- ACTIVE_COMPARATOR
- label
- TH and bilateral salpingo-oophorectomy (TH/BSO)
- description
- Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
- interventionNames
- Procedure: TH/BSO
- Procedure: BPLND
Primary outcomes (1)
- measure
- Disease-free survival (DFS)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * FIGO stage: ⅠA, endometrial carcinoma; * Female, Chinese women; * premenopausal women； * ≤ 50 years old; * Pathological diagnosis by curettage/hysteroscopy : G1 * No prior treatment; * Provide written informed consent. Exclusion Criteria: * The suspicious metastasis of ovarian; * Family history of ovarian cancer; * Suffering from other malignancies; * Concurrently participating in other clinical trials; * Unable or unwilling to sign informed consents; * Unable or unwilling to abide by protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.